Ulcerative colitis: tofacitinib can benefit patients refractory to other treatments

  • Lair-Mehiri L & al.
  • Dig Liver Dis
  • 12 Nov 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients with moderate to severe active ulcerative colitis (UC) can achieve clinical remission when treated with the oral Janus kinase inhibitor tofacitinib after not responding to treatment with anti-TNF agents or vedolizumab.

Why this matters

  • These findings affirm phase 3 trial results demonstrating the effectiveness and safety of tofacitinib, but in a real-world setting.

Study design

  • Researchers studied consecutive patients with active UC treated with tofacitinib (N=38; women, 39%; median age, 41 [range, 28-52] years; median follow-up, 41.5 weeks) after unsuccessful treatment with anti-TNF agents or vedolizumab.
  • Study outcomes included survival without colectomy, survival without tofacitinib discontinuation, and steroid-free clinical remission and clinical response at weeks 14, 24, and 48.
  • Funding: None disclosed.

Key results

  • 77.1% (95% CI, 59.3%-87.9%) of patients achieved survival without colectomy at week 24 and 70% (95% CI, 50.9%-82.8%) at week 48.
  • 70.2% (95% CI, 52.6%-82.3%) of patients achieved survival without treatment discontinuation at week 24.
  • 34.2% of patients achieved steroid-free clinical remission at week 48.
  • Adverse events occurred in 37% of patients, including 6 severe adverse events and 3 herpes zoster infections.

Limitations

  • The study was retrospective, with a small sample size.